Introduction {#s1}
============

Over the last decade, New Psychoactive Substances (NPS) have become a global phenomenon. The emergence of these substances have been reported in almost 100 countries and territories, and more than 500 NPS have been identified worldwide based on reports by national governments, as well as the EU, and international institutions (UNODC, [@B166], [@B168]) (Figure [1](#F1){ref-type="fig"}). In 2014, in Europe alone, 101 NPS have been detected showing an increase of 25%, as compared to 2013 \[EMCDDA (New psychoactive substances in Europe), [@B57]\]. NPS are able to mimic the effects of controlled substances and are mainly synthetic cannabinoids, stimulants, hallucinogens, and opioids.

![**Number of NPS reported worldwide (2009--2014)**. Adapted from UNODC ([@B166]). ![](fnins-10-00153-i0001.jpg) NPS reported for the first time ![](fnins-10-00153-i0002.jpg) Known NPS reported.](fnins-10-00153-g0001){#F1}

Previous studies show that the use of NPS occurs among different subject groups: school students, partygoers, psychonauts, prisoners, and injecting drug users. Motivations for use include factors such as legal status, availability, and cost, as well as the desire to avoid detection and user preferences for particular pharmacological properties \[González et al., [@B73]; Helander et al., [@B80], [@B81]; EMCDDA (European Drug Report), [@B56]; EMCDDA (New psychoactive substances in Europe), [@B57]\]. Although global research is not available yet about NPS, prevalence of use among the population, single national surveys (with respect to substances and subpopulations) show that the use of NPS amongst the general adult population is relatively low compared with the use of other illicit drugs. However, adolescents use more NPS than illicit drugs mostly because many of them are legal and easily available on the web \[Drug Policy Department Italian Presidency of the Council of Ministers, [@B51]; Fraser, [@B66]; Kikura-Hanajiri et al., [@B99]; EMCDDA (New psychoactive substances in Europe), [@B57]; Hondebrink et al., [@B86]; Palamar et al., [@B134]; Wood et al., [@B189]\].

Similar to many known illicit drugs, NPS can cause severe physical and psychological symptoms that can even result in death \[Drug Policy Department Italian Presidency of the Council of Ministers, [@B50]; Fraser, [@B66]; EMCDDA (European Drug Report), [@B56]; UNODC, [@B168]\]. A recent analysis by the European Drug Emergencies Network, monitoring emergency admissions in the last 5 years in 10 EU countries, found that 9% of all drug-related emergencies involved NPS, primarily synthetic cannabinoids and cathinones (Wood et al., [@B188]). Consequently, there is increasing evidence that NPS play a great role in hospital emergencies and some drug-induced deaths \[EMCDDA (European Drug Report), [@B56]\]. However, the analytical detection of NPS for emergency services is not technically available so far; their recognition by means of second level analysis requires standards solution, methodologies and analytical equipment not accessible to every laboratory yet \[Drug Policy Department Italian Presidency of the Council of Ministers, [@B50]; UNODC, [@B166]; EMCDDA (European Drug Report), [@B56]\]. Therefore, their identification in biological samples, as well as in seized or collected samples, represents one major difficulty.

Notably, the internet is an important marketplace for the sale of NPS. Evidence is emerging of so-called "gray marketplaces"-online sites selling NPS which operate on both the surface as well as the deep web (Deluca et al., [@B46]; Drug Policy Department Italian Presidency of the Council of Ministers, [@B50]; Burns et al., [@B24]; Corazza et al., [@B34]). Therefore, NPS can be sold via the internet to everyone, including young, underage teenagers, with complete anonymity and an easy avoidance of law enforcement and health controls \[Drug Policy Department Italian Presidency of the Council of Ministers, [@B50]; UNODC, [@B166]; EMCDDA (European Drug Report), [@B56]\]. The growth of online and virtual drug markets strongly contributes to the uncontrolled widespread use of these substances, increasing health risks for consumers, and challenging drug control policies.

The largest increase in terms of newly reported NPS involves synthetic cannabinoids, synthetic cathinones, and phenethylamines \[EMCDDA (European Drug Report), [@B56]; EMCDDA (New psychoactive substances in Europe), [@B57]\]. The first synthetic cannabinoids were identified in 2008 in preparations called "herbal mixtures" or "herbal blends" (i.e., Spice) and sold as incense or air fresheners. Their effects are similar, if not superior, to those caused by cannabis consumption (Hohmann et al., [@B85]; Khullar et al., [@B98]; Mills et al., [@B123]). Recently, a survey of the use of synthetic cannabinoids among US students showed that Spice products were the second most used drug after marijuana, with a prevalence of 7.4--7.9% in those aged between 15 and 18 years (Johnston et al., [@B91]). Adolescence, a critical developmental period commonly associated with an increase in drug abuse in the human population, may be a stage of particular vulnerability to the effects of the new psychoactive drugs (Johnston et al., [@B91]). In fact, most of the brain receptor systems have been shown to mature slowly, reaching maximal levels around age 20. Indeed, the use of these drugs might influence neurodevelopment inducing psychiatric disorders or other mental deficits (Paus, [@B137]; Sussman et al., [@B158]). Several NPS such as mephedrone, pentedrone and MDPV which mimic the effects of amphetamine-like stimulants (ATS), can be classified as synthetic cathinones with stimulant and empathogenic properties, or as phenethylamines which can induce stimulant and hallucinogenic effects (UNODC, [@B166], [@B168]). Similar to other NPS, synthetic cannabinoids and ATS are largely available online and are often sold as research chemical components. They are mainly produced in Eastern Europe, Central Asia and China, and then shipped and sold to Europe and the USA (UNODC, [@B168]).

Currently, not all NPS are under international control. Many countries worldwide have established permanent control measures for some substances or issued temporary bans \[EMCDDA (New psychoactive substances in Europe), [@B57]; UNODC, [@B168]\]. Only a few NPS have been reviewed by the mechanisms established under the international drug conventions. Existing laws covering issues unrelated to controlled drugs, such as consumer safety legislation, have been used in some countries such as Poland and UK; in others (Hungary, Finland, Italy, France, Denmark, etc.) existing drug laws or processes have been extended or adapted; additionally, in Ireland, Austria, Portugal, Romania, and Sweden new legislation has been designed \[EMCDDA (New psychoactive substances in Europe), [@B57]; UNODC, [@B168]\].

The forensic identification of NPS is very difficult. These may concern the lack of knowledge on NPS available to the professionals performing analytical analysis. In addition, analytical methodologies are still not sufficient to detect the presence of all of the NPS in the analyzed samples and many laboratories lack appropriate analytical equipment for their recognition (Drug Policy Department Italian Presidency of the Council of Ministers, [@B49]). These are all important aspects to take into account when considering the legal, health, and social consequences related to NPS.

To date, several behavioral, neurochemical, and electrophysiological studies have helped us to understand the pharmacological mechanisms of action of NPS. However, many of them have been focused on the acute toxicological consequences of NPS use. As they are relatively new and novel, there are no epidemiological studies to show the long-term effects of these psychoactive compounds. Also, there is not a lot of evidence on the addictive properties of NPS.

This work has been divided into two main parts based on pharmacological classification of the most popular and public health-concerning NPS classes: amphetamine-like stimulants and cannabimimetic drugs. Moreover, specific references to recent papers by the authors have been presented. A thorough analysis of the rewarding and reinforcing properties of NPS and their abuse liability will hopefully, provide to be useful for understanding the new disturbing trends in the field of drug addiction and provide strategies to tackle this growing problem.

NPS: from chemistry to pharmacological effects {#s2}
==============================================

NPS can be divided into six chemical classes (Martinotti et al., [@B116]; Schifano et al., [@B146]): *phenethylamines, piperazines, tryptamines, synthetic cathinones, alkylindoles (synthetic cannabinoids) and arylcyclohexylamines* (see Table [1](#T1){ref-type="table"}). Alternatively, a different classification is based on pharmacological and clinical effects: stimulants, entactogens, hallucinogens, and cannabis-like compounds.

###### 

**New Psychoactive Substances (NPS) classification**.

  **Chemical class**         **Pharmacological effects**                                                                                                                                                    **References**
  -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------
  *Phenethylamines*          Serotoninergic receptor agonists that cause psychedelic effects and inhibit monoamine reuptake                                                                                 Nelson et al., [@B128]
                             Effects: Hypertension, vomiting, hyperthermia, convulsions, dissociation, hallucinations, respiratory deficits, liver and kidney failure, and death in case of overdose        Winstock and Schifano, [@B186]; Schifano et al., [@B144]; Corazza et al., [@B33]; Bersani et al., [@B15]
  *Piperazines*              Stimulants that promote the release of dopamine and noradrenaline and inhibits the uptake of monoamines                                                                        Kersten and McLaughlin, [@B97]; Smith et al., [@B154]
                             Effects: Hyperthermia, convulsions, and kidney failure; hallucinations and death have been reported at high doses                                                              
  *Tryptamines*              5HT2A receptor agonists and serotonin reuptake inhibitors                                                                                                                      Lessin et al., [@B109]; Nichols, [@B129]; Sogawa et al., [@B155]; Fantegrossi et al., [@B61]; Cozzi et al., [@B38]; Fontanilla et al., [@B65]
                             Effects: Visual hallucinations, alterations in sensory perception, depersonalization                                                                                           
  *Synthetic cathinones*     Sympathomimetic drugs that act on serotonin, dopamine, and noradreline pathways                                                                                                Corkery et al., [@B35], [@B37]; Schifano et al., [@B145]; Loi et al., [@B108]
                             Effects: Agitation, restlessness, vertigo, abdominal pain, paranoia, rhabdomyolysis, convulsions, and death                                                                    
  *Synthetic cannabinoids*   CB1 and CB2 receptors agonists displaying higher affinity, efficacy and potency compared to Δ^9^-THC                                                                           Fattore and Fratta, [@B63]; Brents and Prather, [@B20]; De Luca et al., [@B42],[@B44]
                             Effects: Euphoria, anxiolytic, and antidepressant-like effects, paranoia, tachycardia, panic, convulsions, psychosis, visual/auditory hallucinations, vomiting, and seizures   Hermanns-Clausen et al., [@B83]; Winstock and Barratt, [@B185]
  *Arylcyclohexylamine*      Dissociative anesthetics that act as 5HT2A agonist and NMDA receptor antagonist and show high affinity for opioid receptors                                                    Nishimura and Sato, [@B131]; ACMD (Advisory Council on the Misuse of Drugs), [@B5]; Schifano et al., [@B146]
                             Effects: Distort perceptions of sight and sound, dissociation from the environment and selfwithout hallucinations                                                              

*Phenethylamines, piperazines, tryptamines, and synthetic catinones* exhibit stimulant and hallucinogenic effects, making up the distinct class of entactogens, which are described as psychoactive substances that enhance feelings of empathy, love, and emotional closeness to others (Schifano et al., [@B143]). Entactogens can be chemically divided into phenethylamines, amphetamines, synthetic cathinones, piperazines, pipradrols/piperidines, aminoindanes, benzofurans, and tryptamines (see Table [2](#T2){ref-type="table"}). Stimulant drugs usually inhibit monoamine reuptake, increasing the quantity of noradrenaline, dopamine and serotonin in the synaptic cleft leading to sympathomimetic effects (Schifano, [@B142]). *Phenethylamines* are synthetic compounds commercially known as "party pills" (e.g., tablets of different colors/shapes, capsules, powder/crystal). They act on serotoninergic receptors leading to psychedelic effects and some of them inhibit the monoamine reuptake as well (Nelson et al., [@B128]); 3,4-methylenedioxy-methamphetamine (MDMA), widely known as "ecstasy," is one of the most popular drugs among young people because of its stimulant effects. But, recently a growing use of new dangerous molecules on the recreational drug scene, such as 2C and its derivatives (e.g., "N-Bomb," "B-Fly," and "Dr. Death"), 2-D series drugs, 3C-bromo-Dragonfly, 4-MTA, 6-APB, 4,4′-DMAR and MPA, that are novel derivatives of classic psychedelic phenethylamines/MDMA-like drugs (Nelson et al., [@B128]) has been reported; several cases of intoxications have been reported with symptoms such as hypertension, vomiting, hyperthermia, convulsions, dissociation, hallucinations, respiratory deficits, liver, and kidney failure and death in case of overdose (Winstock and Schifano, [@B186]; Schifano et al., [@B144]; Corazza et al., [@B33]; Dean et al., [@B45]; Bersani et al., [@B15]; Le Roux et al., [@B104]; Maas et al., [@B112]). The lead compound in *piperazines*, N-Benzylpiperazin (BZP), has a typical central nervous system stimulant structure so it triggers the release of dopamine and norepinephrine and inhibits the uptake of dopamine, norepinephrine and serotonin (Smith et al., [@B154]). Although BZP is structurally similar to amphetamine, it is reported to have only one-tenth the potency (Wikström et al., [@B182]). However, at higher dosages, hallucinations can be reported as well (Kersten and McLaughlin, [@B97]). Before legal restrictions were placed on it, BZP was used as a safe alternative to amphetamines such as MDMA (Monteiro et al., [@B124]). *Tryptamines* (the most common is the lysergic acid diethylamide-LSD) are a group of monoamine alkaloids, very similar to the endogenous neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) (Tittarelli et al., [@B163]), so they act both as 5HT2A receptor agonists and serotonin reuptake inhibitors (Lessin et al., [@B109]; Nichols, [@B129]; Fantegrossi et al., [@B61]; Cozzi et al., [@B38]; Fontanilla et al., [@B65]) provoking visual hallucinations, alterations in sensory perception, and depersonalization (Sogawa et al., [@B155]); novel tryptamines, as 5-MeO-AMT or 5-MeO-DMT, continue to appear on the online drug market and on the "dark net" (Araújo et al., [@B9]; Schifano et al., [@B146]; Teixeira-Gomes et al., [@B161]). *Synthetic cathinones* (mephedrone, methylone,butylone, MDPV, and α-PVP) are structural analogs of cathinones (a molecule present in the psychoactive plant Khat) and are available in tablets, capsules, powder/crystal and generally labeled as "bath salts" or "plant fertilizers" (Fass et al., [@B62]; German et al., [@B71]; Valente et al., [@B169]; Karila et al., [@B93]). Clinical effects most commonly reported with cathinones include anxiety, impaired concentration and memory, irritation of the nasal mucosa, headache, tachycardia, and hypertension. The typical clinical symptoms are indistinguishable from the acute effects of MDMA or cocaine (Prosser and Nelson, [@B138]; Baumann et al., [@B14]; Valente et al., [@B169]); among their psychoactive effects, agitation, restlessness, vertigo, abdominal pain, paranoia, rhabdomyolysis, convulsions, and death are included (Corkery et al., [@B35], [@B37]; Schifano et al., [@B145]; Loi et al., [@B108]).

###### 

**Chemical classes of stimulant drugs**.

  **Chemical group**                                    **Representatives**                                                                                                                           
  ----------------------------------------------------- ------------------------------------------------------------------------- ------------------------------------------------------------------- --------------------------------
  Phenethylamines                                       2-PEA                                                                     2-phenylethanamine                                                  Teixeira-Gomes et al., [@B161]
  ![](fnins-10-00153-i0003.jpg)                         DMMA                                                                      2-(3,4-dimethoxyphenyl)-Nmethylpropan-2-amine                       
  DMA                                                   N,N-dimethyl-1-phenylpropan-2-amine                                       UNODC, [@B165]                                                      
  β-Me-PEA                                              2-phenylpropan-1-amine                                                                                                                        
  Phenpromethamine                                      N-methyl-2-phenylpropan-1-amine                                           Liechti, [@B106]                                                    
                                                                                                                                  Schifano et al., [@B146]                                            
  Amphetamines                                          PMMA                                                                      1-(4-methoxyphenyl)-N-methylpropan-2-amine                          Iversen et al., [@B90]
  ![](fnins-10-00153-i0004.jpg)                         PMA                                                                       1-(4-methoxyphenyl)propan-2-amine                                   
  4-FMA                                                 1-(4-fluorophenyl)-N-methylpropan-2-amine                                 Zawilska, [@B192]                                                   
  4-CA                                                  1-(4-chlorophenyl)propan-2-amine                                                                                                              
  2-FA                                                  1-(2-fluorophenyl)propan-2-amine                                          Simmler et al., [@B152]                                             
  2-FMA                                                 1-(2-fluorophenyl)-N-methylpropan-2-amine                                                                                                     
  Fenfluramine                                          3-trifluoromethyl-N-ethylamphetamine                                                                                                          
  Synthetic cathinones or beta-keto (bk) amphetamines   4-MMC                                                                     (RS)-1-(4-methylphenyl)-2-methylaminopropan-1-one                   Baumann et al., [@B14]
  ![](fnins-10-00153-i0005.jpg)                         4-EMC                                                                     1-(4-ethylphenyl)-2-(methylamino)propan-1-one                       
  3,4-DMMC                                              1-(3,4-dimethylphenyl)-2-(methylamino)propan-1-one                        Kelly, [@B96]                                                       
  Pentedrone                                            2-(methylamino)-1-phenylpentan-1-one                                                                                                          
  Mephedrone                                            2-(methylamino)-1-phenylpentan-1-one                                      Coppola and Mondola, [@B32]                                         
  Metilone                                              1-(1,3-benzodioxol-5-yl)-2-(methylamino)propan-1-one                                                                                          
  MDPV                                                  1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-ylpentan-1-one                    Paillet-Loilier et al., [@B133]                                     
  αPVP                                                  1-phenyl-2-pyrrolidin-1-ylpentan-1-one                                                                                                        
  bk-PMMA                                               1-(4-methoxyphenyl)-2-(methylamino)propan-1-one                           Schifano et al., [@B146]                                            
                                                                                                                                  Simmler et al., [@B151]                                             
  Piperazines                                           BZP                                                                       N-benzylpiperazine                                                  Iversen et al., [@B90]
  ![](fnins-10-00153-i0006.jpg)                         pCPP                                                                      1-(4-chlorophenyl)-piperazine                                       
  mCPP                                                  1-(3-chlorophenyl)-piperazine                                             Zawilska, [@B192]                                                   
  2C-B-BZP                                              1-\[(4-bromo-2,5-dimethoxyphenyl)methyl\]piperazine                                                                                           
  TFMPP                                                 1-(3-trifluoromethylphenyl)-piperazine                                    UNODC, [@B165]                                                      
  MeOPP                                                 4-methoxyphenylpiperazine                                                                                                                     
  pFPP                                                  4-fluorophenylpiperazine                                                                                                                      
  Pipradrols/Piperidines                                2-DPMP                                                                    2-(Diphenylmethyl)piperidine                                        Zawilska, [@B192]
  ![](fnins-10-00153-i0007.jpg)                         desoxy-D2PM                                                               2-(Diphenylmethyl)pirrolidine                                       
                                                                                                                                  Liechti, [@B106]                                                    
                                                                                                                                  UNODC, [@B165]                                                      
  Aminoidanes                                           2-AI                                                                      2,3-dihydro-1H-inden-2-amine                                        Iversen et al., [@B90]
  ![](fnins-10-00153-i0008.jpg)                         5-IAI                                                                     5-iodo-2,3-dihydro-1H-inden-2-amine                                 
  MDAI                                                  6,7-Dihydro-5H-cyclopenta\[f\]\[1,3\]benzodioxol-6-amine                  UNODC, [@B165]                                                      
  MMDAI                                                 5,6-Methylenedioxy-N-methyl-2-aminoindane                                                                                                     
  MDAT                                                  6,7- Methylenedioxy-2-aminotetralin                                                                                                           
  Benzofurans                                           5-APB                                                                     5-(2-aminopropyl)benzofuran                                         Iversen et al., [@B89]
  ![](fnins-10-00153-i0009.jpg)                         5-APDB                                                                    1-(2,3-dihydro-1-benzofuran-5-yl)propan-2-amine                     
  5-MAPB                                                1-(benzofuran-5-yl)-N-methylpropan-2-amine                                Iversen et al., [@B90]                                              
  6-APB                                                 6-(2-aminopropyl)benzofuran                                                                                                                   
  6-APDB                                                1-(2,3-dihydro-1-benzofuran-6-yl)propan-2-amine                           Corkery et al., [@B36]                                              
  Tryptamines                                           AMT                                                                       1-(1H-indol-3-yl)propan-2-amine                                     Schifano et al., [@B146]
  ![](fnins-10-00153-i0010.jpg)                         5-IT, 5-API                                                               1-(1H-indol-5-yl)propan-2-amine                                     
  5-APDI                                                1-(2,3-Dihydro-1H-inden-5-yl)-2-propanamine                               Teixeira-Gomes et al., [@B161]                                      
  4-AcO-DPT                                             4-Acetoxy-N,N-dipropyltryptamine                                                                                                              
  5-MeO-DPT                                             5-methoxy-N,N-dipropyltryptamine                                          Araújo et al., [@B9]                                                
  4-AcO-DMT                                             4-acetoxy-N,N-dimethyltryptamine                                                                                                              
  4-AcO-DALT                                            4-Acetoxy-N,N-diallyltryptamine                                                                                                               
  5-MeO-AMT                                             5-methoxy-α-methyltryptamine                                                                                                                  
  5-MeO-DMT                                             5-metossi-N,N-dimetiltriptamina                                                                                                               
  2C Agents-substituted phenylethylamines               2C-H                                                                      2,5-dimethoxyphenethylamine                                         Eshleman et al., [@B58]
  ![](fnins-10-00153-i0011.jpg)                         2C-B                                                                      4-bromo-2,5-dimethoxyphenethylamine                                 
  2C-E                                                  2,5-dimethoxy-4-ethylphenethylamine                                       Schifano et al., [@B146]                                            
  2C-N                                                  2,5-Dimethoxy-4-nitrophenethylamine                                                                                                           
  2C-G                                                  2-(2,5-dimethoxy-3,4-dimethylphenyl)ethanamine                            Welter-Luedeke and Maurer, [@B180]                                  
  2D Agents-substituted phenylethylamines               DOI                                                                       1-(4-iodo-2,5-dimethoxyphenyl)-propan-2-amine                       Zawilska, [@B192]
  ![](fnins-10-00153-i0012.jpg)                         DOC                                                                       1-(4-chloro-2,5-dimethoxyphenyl)-propan-2-amine                     
  DOB                                                   1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine                             Gatch et al., [@B69]                                                
  DOM                                                   2,5-Dimethoxy-4-methylamphetamine                                                                                                             
  NBome Agents-substituted phenylethylamines            25H-NBOMe                                                                 1-(2,5-dimethoxyphenyl)-*N*-\[(2-methoxyphenyl)methyl\]ethanamine   Zawilska, [@B192]
  ![](fnins-10-00153-i0013.jpg)                         25I-NBOMe                                                                 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine              
  25B-NBOMe                                             2-(4-bromo-2,5-dimethoxyphenyl)-N-\[(2-methoxyphenyl)methyl\]ethanamine   Schifano et al., [@B146]                                            
  25E-NBOMe                                             2-(2,5-dimethoxy-4-ethylphenyl)-N-(2-methoxybenzyl)ethanamine                                                                                 
  25N-NBOMe                                             2-(2,5-Dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)ethanamine             Kyriakou et al., [@B103]                                            

Synthetic cannabinoids belong to the *alkylindoles* and *cyclohexylphenos* classes which show high affinity for CB1 and CB2 cannabinoid receptors and act like Δ^9^-THC but with prolonged psychoactive effects and more side effects (Fattore and Fratta, [@B63]; Brents and Prather, [@B20]). As shown in Figure [2](#F2){ref-type="fig"}, they can be divided into naphtoylindoles (e.g., JWH- 018, JWH-073, JWH-210, WIN-55212), phenylacetylindoles (e.g., JWH-250 e JWH-251), benzoylindoles (e.g., WIN-48,098, AM-694, RSC-4), cyclohexylphenols (e.g., CP-47497, CP-55940, CP-55244) (Smith et al., [@B154]). They are generally consumed by inhalation through the consumption of cigarettes containing herbal substances as well as these synthetic molecules to obtain euphoria, anxiolytic, and antidepressant-like effects. However, reports presented by the EMCDDA ([@B54]) and by the Italian Early Warning System -- N.E.W.S. (Anti-drug Policies Department) have shown effects like paranoia, tachycardia, panic, convulsions, psychosis, visual/auditory hallucinations, vomiting, and seizures (Hermanns-Clausen et al., [@B83]; Winstock and Barratt, [@B185]).

![**Number of NPS reported by substance group in 2014**. Adapted from UNODC ([@B166]).](fnins-10-00153-g0002){#F2}

Finally, *arylcyclohexylamine* (ketamine, phencyclidine- PCP and methoxetamine) are dissociative anesthetics that distort perceptions of sight and sound and produce feelings of detachment (or dissociation) from the environment and self without hallucinations \[Nishimura and Sato, [@B131]; ACMD (Advisory Council on the Misuse of Drugs), [@B5]\]. Although present in the classification, the rewarding properties of the latter group will not be discussed in this review paper.

Human and animal studies on amphetamine-like stimulants effects: psychoactive effects, cognitive deficits, emotional alterations, and dependence {#s3}
================================================================================================================================================

In the second part of the 90s, a global trend of escalating amphetamine-like stimulant use was observed and synthetic tryptamines appeared on illicit drug markets. Instead of replacing or displacing MDMA and cocaine, mephedrone, and other NPS from this group appear to have been added to the established repertoire of psychostimulant narcotics (Sanders et al., [@B139]; Zawilska, [@B192]).

In animal models of addiction, cathinones have displayed potential rewarding and reinforcing effects. For example, mephedrone produces conditioned place preference (CPP), facilitates intracranial self-stimulation and is self-administered in rats (Hadlock et al., [@B78]; Lisek et al., [@B107]; Motbey et al., [@B125]; Bonano et al., [@B17]; Gregg et al., [@B75]). Prior studies demonstrated that MDPV and methylone, another synthetic cathinone, increase locomotor activity in rodents (López-Arnau et al., [@B110]; Marusich et al., [@B117]; Aarde et al., [@B2]; Gatch et al., [@B70]) and also enhance intracranial self-stimulation (Watterson et al., [@B177], [@B178]; Bonano et al., [@B17]) and engender conditioned place preference (Karlsson et al., [@B94]), effects that are indicators of high abuse potential (Schindler et al., [@B147]). This evidence suggests that each compound could produce behavioral effects consistent with psychostimulant drugs displaying high abuse liability, possibly higher than amphetamine. In fact, in rats trained to self-administer MDPV or methamphetamine, dose-substitution studies demonstrated that behavior was dose-sensitive for both drugs, but MDPV showed greater potency and efficacy than methamphetamine (Paillet-Loilier et al., [@B133]). Moreover, in mice models, mephedrone, methylone, and MDPV produce CPP equal or higher than amphetamine, strongly suggesting their addictive properties (Karlsson et al., [@B94]). In addition, MDMA, methylone, and mephedrone are self-administered in female rats with a higher intake in mephedrone-trained rats compared to methylone-trained animals. This seems to suggest that mephedrone might have greater reinforcing effects compared to methylone or MDMA (Creehan et al., [@B39]), despite their shared mechanism of action. They are non-selective transporter substrates that increase the release of dopamine, norepinephrine and 5-HT *in vitro* (Baumann et al., [@B13]; Eshleman et al., [@B59]; Simmler et al., [@B151]). Importantly, the 5-HT-releasing ability of these drugs is more prevalent than their effects on dopamine *in vivo* (Baumann et al., [@B12], [@B13]; Kehr et al., [@B95]; Wright et al., [@B190]) suggesting empathogen-like effects. Such findings indicate that self-administration of MDMA-like drugs is influenced by 5-HT release, but also drug pharmacokinetics, effects on noradrenergic systems, or non-transporter sites of action (Schindler et al., [@B147]).

In humans, synthetic cathinones produce psychotropic effects similar to MDMA and cocaine (Simmler et al., [@B151]). The typical dose range varies according to the different cathinone derivatives. However, according to information released from users in drug forums, where people discuss their experiences with recreational drugs (e.g., "Drugs-Forum," "Urban 75," "Erowid"), they usually start with a small dose and gradually increase it. This is in line with scientific reports which show that an excessive increase of noradrenergic signals could promote the onset of adverse effects and that the potency of a substance to activate the noradrenergic system is inversely correlated to the doses typically used recreationally (Simmler et al., [@B151]). All cathinones exhibit higher dopaminergic activity when compared with their non β-keto amphetamines analogs. Recent studies of the mechanisms by which b-ketoamphetamines interact with DAT, offer significant insight into why these drugs have such divergent effects on neurotoxicity. "Bath salts" have been classified as substrates and non-substrates based on whether or not they are transported by the DAT (Anneken et al., [@B7]). This increased dopaminergic property of the cathinones suggests higher stimulant-type effects and a greater risk for dependence (Aarde et al., [@B2]). Stimulant and entactogenic properties are typical of cathinones. In fact, desired or pleasant effects most often described by users include euphoria, intensification of sensory senses, increased sociability, increased energy, mental stimulation, empathy connection, openness, increased sensory perception, decreased inhibition, and sexual arousal; but side effects such as cognitive confusion, cognitive impairment, psychiatric irritability, aggression that sometimes progresses to violent or even criminal behavior, and self-destructive behavior have also been reported \[IACP (International Association of Chiefs of Police), [@B88]\]. MDPV and mephedrone have been directly implicated in a number of fatalities in medical literature. In one case involving MDPV, the cause of death was consistent with excited delirium syndrome, a condition associated with stimulant drug overdose and attributable to excessive dopaminergic transmission (Baumann et al., [@B13]).

However, amphetamine remains the prototype of psychostimulants causing agitation, insomnia, loss of appetite and, at higher doses, "amphetamines psychosis" characterized by paranoia, hallucinations and delusion (Iversen et al., [@B90]). In experimental animals, low doses of amphetamine cause hyperactivity and higher doses lead to stereotyped repetitive behaviors (Whelpton, [@B181]). The neurotoxic effects of amphetamines has been vastly studied and their ability to damage brain monoaminergic cells was shown by long-term deficits in dopaminergic and serotoninergic systems in several brain areas of animals (Teixeira-Gomes et al., [@B161]). One of the major neurotoxic actions of amphetamines observed in laboratory animals is the sustained depletion of monoamine brain levels. In addition to the damage to dopaminergic and serotoninergic neuronal systems, amphetamines can also induce neuronal death. For example, in several studies, MDMA administration in mice and rats produced neuronal death in several brain areas including the cortex, hippocampus, amygdala, ventromedial/ventrolateral thalamus, and teniatecta (Teixeira-Gomes et al., [@B161]). MDMA is still one of the most widely used recreational drugs and many NPS were designed to mimic its effects or as substitutes for MDMA in ecstasy pills.

The potency of abused psychostimulants to activate the brain reward circuitry increases the risk of potential for abuse and addiction in humans (Table [3](#T3){ref-type="table"}). In contrast, a relative activation of the serotonin system would be linked to a reduction in abuse potential. Thus, the DAT/SERT inhibition ratio and dopamine/serotonin release potency has been proposed to predict the effects of psychostimulants in humans (Paillet-Loilier et al., [@B133]). Data currently available has shown that the frequent consumption of high doses of synthetic cathinones induce tolerance, dependence, craving, and withdrawal syndrome after sudden suspension \[NDIC (National Drug Intelligence Center), [@B126]\]. Indeed, Kehr et al. ([@B95]) showed that mephedrone induces a stimulation of the dopamine transmission in the nucleus accumbens, that might be a starting point for developing drug-addiction (Volkow et al., [@B174]; Di Chiara et al., [@B48]). Although the typical dose range of MDPV appears to be between 5 and 30 mg in a single administration, some users reported tolerance with the consumption of a single dose, higher than 200 mg (Coppola and Mondola, [@B32]). Several users have reported a withdrawal syndrome after abrupt cessation of long-term use of methcathinone, mephedrone and MDPV (Winstock et al., [@B187]). Moreover, Gatch et al. ([@B70]) showed that all of the cathinone derivatives fully substituted for methamphetamine or cocaine in drug discrimination tests. Results suggest that these drugs are comparable to cocaine and methamphetamine, and are likely to induce dependence (Iversen et al., [@B90]).

###### 

**Studies related to the rewarding properties of amphetamine-like stimulants**.

  **Substance**                                                            **Dosage Regimen**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Studies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   **References**
  ------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------
  Desoxypipradrol                                                          Rat brain slices from the nucleus accumbens core were exposed to desoxypipradrol (1, 3, or 10 μM) for 60 min                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Dopamine efflux was electrically evoked and recorded using fast cyclic voltammetry. Desoxypipradrol increased the peak dopamine efflux and also slowed dopamine re-uptake. Desoxypipradrol was more potent than cocaine causing a seven fold increase in peak dopamine levels and increasing dopamine re-uptake half-life 15-fold                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Davidson and Ramsey, [@B40]
  5-APB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Voltammetric studies in rat accumbens brain slices revealed that 5-APB slowed dopamine reuptake, and at high concentrations caused reverse transport of dopamine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Dawson et al., [@B41]
  Pentedrone                                                               Pentedrone at 3 and 10 mg/kg significantly increased conditioned place preference in mice, while pentedrone at 0.3 mg/kg/infusion significantly increased self-administration in rats                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Pentedrone produces CPP in mice and self-administration in rats. These results demonstrate the abuse liability of pentedrone in both models                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Hwang et al., [@B87]
  MDPV                                                                     Rats were trained to intravenously self-administer MDPV in daily 2 hr sessions for 10 days at doses of 0.05, 0.1, or 0.2 mg/kg/infusion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         MDPV has reinforcing properties and activates brain reward circuitry, suggesting a potential for abuse and addiction in humans                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Watterson et al., [@B178]
  1-Benzylpiperazine                                                       1.25, 5, and 20 mg/kg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           1-benzylpiperazine induced place preference in the rat, which indicates that the compound possesses rewarding properties                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Meririnne et al., [@B122]
  Methamphetamine                                                          Intravenous infusions of methamphetamine (0.15 mg/kg) in human volunteers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Intravenous methamphetamine administration produces activity in reward- and affect-related areas of the human brain including the medial orbitofrontal cortex, the rostral anterior cingulate cortex and the (ventral) striatum                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Völlm et al., [@B175]
  Mephedrone                                                               Mephedrone was quantified between 96 and 155 mg in each tablet                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Mephedrone induced strong feelings of craving in most users                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Brunt et al., [@B23]
  Mephedrone                                                               MMC was self-administered via the intravenous route. MMC 0.1/1 mg/kg/ infusion, METH 0.01/0.3 mg/kg/ infusion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   METH, but not MMC, self-administration elevated TSPO (inflammation marker translocator protein) receptor density in the nucleus accumbens and hippocampus, while MMC, but not METH,self-administration decreased striatal 5-hydroxyindolacetic acid (5-HIAA) concentrations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Motbey et al., [@B125]
  *R*-mephedrone (*R*-MEPH) *S*-mephedrone (*S*-MEPH)                      Saline, *R*-MEPH or *S*-MEPH was given for 7 days using the following doses: day 1 (15 mg/kg *R*-MEPH/*S*-MEPH or saline), days 2--6 (30 mg/kg *R*-MEPH/*S*-MEPH or saline), day 7 (15 mg/kg *R*-MEPH/*S*-MEPH or saline) Following 10 days of drug abstinence, all groups were injected with 15 mg/kg*R*-MEPH                                                                                                                                                                                                                                                                                                                                                                                  Stereospecific effects of MEPH enantiomers suggest that the predominant dopaminergic actions of *R*-MEPH (i.e., the lack of serotonergic actions) render this stereoisomer more stimulant-like when compared with *S*-MEPH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Gregg et al., [@B75]
  Amphetamine Mephedrone Methylone MDPV                                    All drugs were dissolved in physiological saline and administered (i.p.) at doses of 0.5, 2, 5, 10 or 20 mg/kg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Mephedrone, methylone and MDPV produce CPP equal or higher than amphetamine strongly suggesting addictive properties                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Karlsson et al., [@B94]
  Mephedrone Methylenedioxymethamphetamine Methamphetamine Methcathinone   4-10 or 25 mg/kg s.c.per injection, 2-h intervals, administered in a pattern used frequently to mimic psychostimulant "binge" treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Results revealed that, repeated mephedrone injections cause a rapid decrease in striatal dopamine (DA) and hippocampal serotonin (5-hydroxytryptamine; 5HT) transporter function. Mephedrone also inhibited both synaptosomal DA and 5HT uptake. Like methylenedioxymethamphetamine, but unlike methamphetamine or methcathinone, repeated mephedrone administrations also caused persistent serotonergic, but not dopaminergic, deficits. However, mephedrone caused DA release from a striatal suspension approaching that of methamphetamine                                                                                                                                                                                                                                                               Hadlock et al., [@B78]
  Mephedrone                                                               Motor activity experiments: rats were injected with mephedrone (0.5, 1, 3, 5, 10, 30 mg/kg); CPP experiments: animals received two conditioning sessions per day, one with an injection of mephedrone (3, 10, 30 mg/kg) and the other with an injection of saline                                                                                                                                                                                                                                                                                                                                                                                                                               In conclusion, mephedrone displayed locomotor stimulant properties that were dependent on increased dopamine transmission and place conditioning effects that were suggestive of rewarding properties. Those behavioral findings correlate well with neurochemical studies demonstrating that mephedrone acts as a substrate for plasma membrane monoamine transporters, evokes transporter mediated-release of monoamines through reversal of normal transporter flux, and enhances extracellular levels of dopamine and serotonin in the rat nucleus accumbens                                                                                                                                                                                                                                              Lisek et al., [@B107]
  Methcathinone                                                            Methcathinone (0.1--1.0 mg/kg),                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 All compounds facilitated ICSS (intracranial self-stimulation) at some doses and pretreatment times, which is consistent with abuse liability for each of these compounds. However, efficacies of compounds to facilitate ICSS varied, with methcathinone displaying the highest efficacy and mephedrone the lowest efficacy to facilitate ICSS                                                                                                                                                                                                                                                                                                                                                                                                                                                               Bonano et al., [@B17]
  MDPV                                                                     MDPV (0.32--3.2 mg/kg),                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Methylone                                                                Methylone (1.0--10 mg/kg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Mephedrone                                                               Mephedrone (1.0--10 mg/kg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  MDPV alpha-PVP                                                           Self-administration: Separate groups of rats were trained to selfadminister MDPV (*N* = 18; 0.05 mg/kg/infusion) or alpha-PVP (*N* = 9; 0.1 mg/kg/infusion, *N* = 18; 0.05 mg/kg/infusion). Telemetry procedure: Seven treatment conditions (Veh; 1, 5.6, and 10 mg/kg of alpha-PVP and MDPV) were counterbalanced and drugs were injected i.p. (1.0 ml/kg volume) with a 3--4-day interval between sessions                                                                                                                                                                                                                                                                                    The potency and efficacy of MDPV and alpha-PVP were very similar across multiple assays, predicting that the abuse liability of alpha-PVP will be significant and similar to that of MDPV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Aarde et al., [@B1]
  Methylone MDPV Mephedrone Methamphetamine                                Mice were treated with methylone (30 mg/kg), MDPV (30 mg/kg), or mephedrone (40 mg/kg) using a binge-like regimen comprised four injections with a 2-h interval between each injection. For combination treatment of mice with methylone or MDPV with methamphetamine, mice were treated with varying doses of either bketoamphetamine (49 -- 10, 20, or 30 mg/kg) concurrent each injection of varying doses of methamphetamine (49 -- 2.5, 5, or 10 mg/kg). To determine if MDPV neuroprotection would extend to non-amphetamine neurotoxins, mice were treated with MDPV (29 -- 10 mg/kg) prior to each of two injections of MPTP (20 mg/kg). All injections were given via the i.p. route   The b-ketoamphetamines alone or in all possible two-drug combinations do not result in damage to DA nerve endings but do cause hyperthermia. MDPV completely protects against the neurotoxic effects of ethamphetamine while methylone accentuates it. Neither MDPV nor methylone attenuates the hyperthermic effects of methamphetamine. The potent neuroprotective effects of MDPV extend to amphetamine-, 3,4-methylenedioxymethamphetamine-, and MPTP-induced neurotoxicity. These results indicate that b-ketoamphetamine drugs that are non-substrate blockers of the DA transporter (i.e., MDPV) protect against methamphetamine neurotoxicity, whereas those that are substrates for uptake by the DA transporter and which cause DA release (i.e., methylone, mephedrone) accentuate neurotoxicity   Anneken et al., [@B7]
  MDPV Methylone                                                           Self-administration studies in Rats: initial acquisition doses were 0.03 mg/kg/inj for MDPV, 0.3 or 0.5 mg/kg/inj for methylone, and 0.5 mg/kg/inj for cocaine. Microdialysis studies in Rats: drugs were administered i.v.to mimic the selfadministration route. For MDPV, rats received 0.1 mg/kg followed by 0.3 mg/kg. For methylone, rats received 1.0 mg/kg followed by 3 mg/kg                                                                                                                                                                                                                                                                                                           This study support the hypothesis that elevations in extracellular 5-HT in the brain can dampen positive reinforcing effects of cathinone-type drugs. Nevertheless, MDPV and methylone are both self-administered by rats, suggesting these drugs possess significant abuse liability in humans                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Schindler et al., [@B147]
  Methylone                                                                Rats were randomly assigned to one of four groups based upon methylone dose (0.05, 0.1, 0.2, or 0.5 mg/kg per infusion)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         This study reveal that methylone may possess an addiction potential similar to or greater than MDMA, yet patterns of self-administration and effects on brain reward function suggest that this drug may have a lower potential for abuse and compulsive use than prototypical psychostimulants                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Watterson et al., [@B177]
  Mephedrone Methylone MDMA                                                Groups of female Wistar rats were trained to self-administer mephedrone, methylone or MDMA (0.5 mg/kg/inf) under a Fixed-Ratio (FR) 1 schedule of reinforcement for 14 sessions. Following the acquisition interval, animals were evaluated in FR (0.0, 0.125, 0.25, 0.5, 1.0, 2.5 mg/kg/inf) and Progressive-ratio- PR (0.125, 1.0 mg/kg/inf) dose-substitution procedures                                                                                                                                                                                                                                                                                                                     The results show that female rats acquired the self-administration of all three compounds with intakes in mephedrone-trained rats that were significantly higher than that of methylone-trained or MDMA-trained rats. In doses substitution under either FR or PR contingencies, however, the potencies of all three drugs were similar within the original training groups. The mephedrone-trained animals exhibited higher intakes of all drugs during dose-substitution, indicating lasting consequences of the training drug. Abuse liability of these three compounds is therefore predicted to be similar in established stimulant users but may differ in liability if they are primary drugs of initiation                                                                                            Creehan et al., [@B39]
  Mephedrone                                                               Mephedrone (1 or 3 mg/kg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       The neurochemical and functional properties of mephedrone resemble those of MDMA, but it also shows an amphetamine-like effect in that it evokes a rapid release and elimination of DA in the brain reward system, a feature that may contribute to its potent re-inforcing properties                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Kehr et al., [@B95]
  (+)-amphetamine MDMA                                                     MDMA (3 mg/kg) (+)-amphetamine (1 mg/kg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

Synthetic marijuana and the cannabimimetics {#s4}
===========================================

Spice and CB1 "super agonists"
------------------------------

*Synthetic Cannabimimetic agents* (SC), also known as *Cannabimimetics*, are substances with pharmacological properties similar to delta-9-tetrahydrocannabinol (Δ^9^-THC) assessed by *in vitro* and *in vivo* animal studies such as binding studies and functional assays (Compton et al., [@B31]; EMCDDA, [@B55]). SC have been detected in "Spice," "K2," and spice-like samples all over the world. Spice is a smokable herbal mixture marketed as a safe, legal alternative to Cannabis, composed by shredded plant material laced with a variety of SC compounds \[NIDA (National Institute on Drug Abuse), [@B130]\]. These compounds are "smokable" since they are small (typically 20--26 carbon atoms) and highly lipophilic molecules. A few hundred of SC of the JWH, HU, and CP series are currently available. They retain very high cannabinoid receptor binding affinity levels, with a dose-response efficacy significantly higher than Δ^9^-THC itself (Brents et al., [@B21]; Fattore and Fratta, [@B63]; Schifano et al., [@B146]). New legal regulations have been enacted to control the global diffusion of Spice. As a consequence of that, three subsequent generations of SC have been developed based on slight modifications of the first generation compounds such as JWH-018, CP 47,497, and HU-210 \[ACMD (Advisory Council on the Misuse of Drugs), [@B3]\] that are full CB1 agonists with affinities that are 4.5, 8.6, and 55 times that of Δ^9^-THC, respectively.

Different European countries, in 2009, and some states in the US, in 2010, banned the sale and use of first generation SC. These regulations induced an extreme reduction of these SC in the Spice/K2 preparations with a subsequent increase of newly synthetized SC, thus belonging to the "second" (e.g., AM-2201, MAM 2201, AM-694, RCS-4) and "third" (e.g., PB-22 "QUPIC," 5F-PB-22, BB-22 "QUCHIC," AB-PINACA) generation \[ACMD (Advisory Council on the Misuse of Drugs), [@B4], [@B6]\] in order to avoid detection.

Several studies show that SC are remarkably different from and more dangerous than THC. Indeed, while THC is a partial CB1 agonist, *in vitro* studies have clearly shown that these compounds are full agonists with higher potency and efficacy as compared to Δ^9^-THC (Atwood et al., [@B10], [@B11]; Marshell et al., [@B114]). More recent studies have been shown that selected third generation compounds, such as 5F-PB-22 and BB-22, retain greater CB1 receptor agonist potency (five- and seven- fold, respectively) and efficacy and a higher binding affinity (26- and 30-fold, respectively) at CB1 receptors compared to JWH-018 (De Luca et al., [@B44]).

Moreover, studies performed in rats and mice showed that many SC displayed locomotor depressant effects and a characteristic tetrad profile at lower doses compared to Δ^9^-THC (Chaperon and Thiébot, [@B26]; Wiley et al., [@B183], [@B184]; Gatch and Forster, [@B67], [@B68]; Vigolo et al., [@B164]). In addition, JWH-018 and its congeners are readily metabolized to a series of cannabimimetics (Seely et al., [@B149]). That, together with the presence of several different SC in Spice/K2 products and their unpredictable dosing when consumed (Kronstrand et al., [@B101]), might explain their acute severe toxicity and even lethal medical complications in humans (Brents et al., [@B21]; Papanti et al., [@B136]; Brents and Prather, [@B20]; Brewer and Collins, [@B22]; Santacroce et al., [@B140]), leading to severe withdrawal syndrome and dependence as well in some cases (Zimmermann et al., [@B193]; Gunderson et al., [@B77]; Macfarlane and Christie, [@B113]). In addition, clinical evidence indicates that JWH-018 can generate/cause psychosis in vulnerable individuals (Every-Palmer, [@B60]). Notably, SC misuse has been associated with anxiety, agitation/panic attacks, paranoid ideation, suicidal ideation, and hallucinations (Fattore and Fratta, [@B63]; Wells and Ott, [@B179]; Thomas et al., [@B162]; Besli et al., [@B16]), and also been related to mood, cognitive (i.e., memory impairment, attention difficulties), neurological (i.e., dizziness, sensation changes, seizures, tremor) and psychotic (i.e., agitation, aggression, catatonia, paranoia, hallucinations, depersonalization, dissociation, prolonged psychosis, perceptual alterations) episodes, with a higher incidence in comparison to those seen with Δ^9^-THC use (Papanti et al., [@B136]; Spaderna et al., [@B157]; Van Amsterdam et al., [@B171]).

Rewarding and reinforcing properties of cannabimimetics
-------------------------------------------------------

Recent literature shows that SC have emerged as new drugs of abuse. As previously reported, an incredibly huge number of SC have been detected in Marijuana substitutes (Denooz et al., [@B47]; Brents and Prather, [@B20]; Maxwell, [@B120]). Being CB1 receptor agonists with extremely high affinity, SC probably act in brain regions where CB1 receptors are heavily expressed, such as the amygdala, cingulate cortex, prefrontal cortex (PFC), ventral pallidum, caudate putamen, nucleus accumbens (NAc), ventral tegmental area (VTA), and lateral hypothalamus (Glass et al., [@B72]; Wang et al., [@B176]). All these brain regions have a recognized involvement in reward, addiction and cognitive functions (Koob and Volkow, [@B100]). Furthermore, CB1 receptors are located in limbic regions, such as VTA, NAc, ventral pallidum, CeA, BNST, and PFC (Herkenham et al., [@B82]; Glass et al., [@B72]; Wang et al., [@B176]); the integration of excitatory and inhibitory inputs, coming from these structures, influence, and modulate reward processing (Sidhpura and Parsons, [@B150]; Panagis et al., [@B135]). Several studies in mice and rats showed that these compounds affect the mesolimbic dopaminergic transmission and influence conditioned behaviors (Table [4](#T4){ref-type="table"}). Similar to other drugs of abuse, THC activates dopamine (DA) transmission in the ventral striatum in humans (Volkow et al., [@B174]; Bossong et al., [@B18]). In addition, animal studies showed that both Δ^9^-THC and WIN 55.212-2, a CB1 and CB2 agonist, elicit dopamine release in the NAc (Chen et al., [@B30]; Cheer et al., [@B29]) with a specific activation of the NAc shell subregion (Tanda et al., [@B159]; Lecca et al., [@B105]; De Luca et al., [@B43]). The NAc plays a crucial role in brain reward circuits involved in motivational and cognitive functions (Heimer et al., [@B79]; Zahm and Brog, [@B191]). In particular, it has been shown that stimulation of DA transmission in the NAc shell is directly involved in the rewarding properties of both natural reward and addictive drugs (Di Chiara et al., [@B48]). Microdialysis studies on awake freely moving animals performed in our laboratories showed that JWH-018, at the dose of 0.25 mg/kg i.p., increases DA transmission in the NAc shell but not in the NAc core nor in mPFC (**Figure 4**). Surprisingly, DA transmission in the NAc shell was not stimulated after administration of lower (0.125 mg/kg ip) or higher (0.5 mg/kg ip) doses producing an inverted U-shape dose response curve for the effect of JWH-018 (De Luca et al., [@B42]). Further studies in mice and rats showed a similar effect after the intraperitoneal administration of JWH-073 and JWH-250 as well (Ossato et al., [@B132]), and after the intravenous administration of BB-22 (De Luca et al., [@B44]). Notably, as previously reported by De Luca et al. ([@B43]), THC stimulated extracellular DA release in the NAc shell at a dose fourfold higher than JWH-018 when administered intraperitoneally. In addition, BB-22 stimulates NAc shell DA release at the dose of 0.01 mg/kg iv, while THC increases extracellular DA in the same area at dose of 0.15 mg/kg iv (Tanda et al., [@B159]). These results show that both JWH-018 and BB-22 are more potent than THC in inducing NAc shell DA release, suggesting a putative higher abuse liability of synthetic vs. natural cannabinoids. Electrophysiological studies show that the stimulation of DA extracellular levels in the NAc shell by JWH-018 is thought to be due to the activation of CB1 receptors located on presynaptic GABAergic afferents directed to VTA DA neurons, leading to a reduction of GABA~A~ receptors mediated inhibition of DA neuronal activity in the VTA (Lupica and Riegel, [@B111]; Mátyás et al., [@B118]; Melis et al., [@B121]; De Luca et al., [@B42]). Rewarding effects of cannabimimetics have also been assessed by different experimental paradigms such as intracranial self-stimulation (ICSS), place conditioning tests, drug-discrimination and intravenous self-administration (IVSA) studies. ICSS of the medial forebrain bundle is the operant conditioning method used in rodents to evaluate the role of the mesolimbic dopamine pathway in rewarding behavioral effects (Carlezon and Chartoff, [@B25]) and evaluating potential of abuse (Negus and Miller, [@B127]). Not surprisingly, to date no data on the effect of new SC on ICSS are available. Δ^9^-THC does not facilitate ICSS, but has a dose-dependent inhibitory influence on ICSS (Vlachou et al., [@B173]). Similarly, a depression of ICSS is observed after the administration of WIN55212-2, CP55940, HU210 (Antoniou et al., [@B8]; Vlachou et al., [@B172]; Mavrikaki et al., [@B119]). Differences in developing tolerance to depression of ICSS after repeated exposure to cannabinoids have been reported. Tolerance is completely developed after repeated exposure to Δ^9^-THC (Kwilasz and Negus, [@B102]) but partially developed after CP55940 (Grim et al., [@B76]), and not developed after WIN55212-2 administration (Mavrikaki et al., [@B119]), suggesting that the different affinity of Δ^9^-THC vs. SC for the CB1 receptors could play a role in developing this tolerance (Grim et al., [@B76]).

###### 

**Studies related to the rewarding properties of cannabimimetics**.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Substance**          **Dosage Regimen**                                                                                                                                                                                                                                                                                                                                                                                                                                **Studies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                **References**
  ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------
  WIN 55212-2            Intravenous self-administration model in drug-naive mice of WIN 55212-2 (0.5 and 0.1 mg/kg per injection)                                                                                                                                                                                                                                                                                                                                         WIN 55,212-2 was intravenously self-administered by mice in a concentration-dependent manner according to a bell-shaped curve                                                                                                                                                                                                                                                                                                                                              Martellotta et al., [@B115]

  HU210                  Conditioned place preference (CPP) in male rats: HU210 (20, 60 and 100 μg/kg), and Δ^9^-THC (1.5 mg/kg)                                                                                                                                                                                                                                                                                                                                           HU210 and Δ^9^-THC produced aversion as expressed by time spent in the drug-paired compartment of the CPP apparatus                                                                                                                                                                                                                                                                                                                                                        Cheer et al., [@B28]

  WIN 55212-2            Intravenous SA in rats WIN 55,212-2 at doses ranging from 6.25 to 50 μg/kg per injection, under a fixed-ratio 1 (FR1) schedule of reinforcement and nose-pokes as the operant responses                                                                                                                                                                                                                                                           Response rate depended on the drug dose available, with maximum rates occurring at 12.5 microg/kg per injection                                                                                                                                                                                                                                                                                                                                                            Fattore et al., [@B64]

  WIN 55212-2            Fast-scan cyclic voltammetry: systemic administration at a dose of 125 μg/kg                                                                                                                                                                                                                                                                                                                                                                      WIN55,212--2 enhances dopamine transients but depresses electrically evoked release                                                                                                                                                                                                                                                                                                                                                                                        Cheer et al., [@B29]

  WIN 55212-2\           After Intracranial self-stimulation (ICSS) of the medial forebrain bundle, rats received intraperitoneal injections of WIN 55,212-2 (graded doses 0.1, 0.3, 1 and 3 mg/kg), CP 55,940 (graded doses 10, 30, 56 and 100 μg/kg), or HU-210 (graded doses 10, 30, 100 μg/kg)                                                                                                                                                                         With the exception of the highest dose of all cannabinoid agonists tested, which significantly increased the threshold frequency required for ICSS into the medial forebrain bundle, all other doses of the tested drugs did not affect ICSS thresholds. The CB1 receptor antagonist SR141716A reversed the actions of WIN 55,212-2 and CP 55,940, but not HU-210                                                                                                          Vlachou et al., [@B172]
  CP 55940\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  HU-210                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  WIN 55212-2            Intravenous self-administration (SA). Rats, trained for 3 weeks to self-administer WIN 55,212-2 (12.5 μg/kg) in single daily 1-h sessions under a fixed ratio 1 (FR 1) schedule, then switched to FR 2 for a further week. During SA sessions, microdialysis assays were performed every 3rd day, and then daily starting from the 13th session. Dialysate DA from the NAc shell and core was monitored before, during, and for 30 min after SA   Response-contingent WIN 55,212-2 SA preferentially increases the NAc shell DA output as compared to that of the core independently from the duration of the WIN 55,212-2 exposure. Increase in NAc DA is strictly related to WIN 55,212-2 actions because it is not observed during extinction despite active responding                                                                                                                                                   Lecca et al., [@B105]

  WIN 55212-2            Rats received intraperitoneal injections of WIN55,212-2 (0.1, 0.3 or 1 mg/kg) for 20 subsequent days. Thresholds for ICSS were measured before and after each injection                                                                                                                                                                                                                                                                           WIN55,212-2 (1 mg/kg) significantly increased ICSS thresholds from the first day of administration, an effect that remained stable across the subsequent days of administration. These findings indicate that repeated WIN55,212-2 administration elicited a sustained increase in ICSS                                                                                                                                                                                    Mavrikaki et al., [@B119]

  JWH-018\               Adult male rats trained to discriminate 3 mg/kg Δ(9)-THC or 0.3 mg/kg JWH-018 from vehicle                                                                                                                                                                                                                                                                                                                                                        JWH-018, JWH-073, and JWH-210 fully substituted in Δ(9)-THC-trained rats and Δ(9)-THC substituted in JWH-018-trained rats                                                                                                                                                                                                                                                                                                                                                  Wiley et al., [@B184]
  JWH-073\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  JWH-210                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  JWH-018\               These compounds were then tested for substitution in rats trained to discriminate Δ-THC (3 mg/kg, intraperitoneally)                                                                                                                                                                                                                                                                                                                              Each of the compounds fully substituted for the discriminative stimulus effects of Δ-THC, mostly at doses that produced only marginal amounts of rate suppression. JWH-250 and CP 47,497-C8-homolog suppressed response rates at doses that fully substituted for Δ-THC                                                                                                                                                                                                    Gatch and Forster, [@B67]
  JWH-073\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  JWH-250\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  JWH-200\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  JWH-203\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  AM-2201\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  CP 47,497-C8-homolog                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  CP 55940               Acute and repeated administration (7 days) of CP55,940 (0.12-0.18)mg/kg).on operant responding for electrical brain stimulation of the medial forebrain bundle in C57BL/6J mice                                                                                                                                                                                                                                                                   CP55,940 attenuated ICSS in a dose-related manner. This effect was blocked by the CB1 receptor antagonist rimonabant                                                                                                                                                                                                                                                                                                                                                       Grim et al., [@B76]

  JWH-018                Microdialysis studies in rats: 0.125 mg/kg ip 0. 25 mg/kg ip 0. 5 mg/kg ip Rats self-administered JWH-018 (20 μg/kg/infusion) in single daily 1 h FR3 sessions. C57BL/6 mice self-administered JWH-018 (30 μg/kg/infusion) in single daily 2 h FR1 sessions                                                                                                                                                                                       JWH-018 0.25 mg/kg ip increases dopamine transmission in Nac shell, but not in NAc core nor in mPFC. The lower and the higher doses do not stimulate DA transmission so the dose-response curve of this compound has an inverted U-shape. Both rats and mice readily acquired two different operant behaviors: nose-poking into an optical switch (rats) and lever-pressing (mice)                                                                                         De Luca et al., [@B42]

  BB-22\                 Microdialysis studies in rats: BB-22 (0.003-0.01 mg/kg i.v.) 5F-PB-22 (0.01 mg/kg i.v.) 5F-AKB-48 (0.1 mg/kg i.v.) STS-135(0.15 mg/kg i.v.)                                                                                                                                                                                                                                                                                                       BB-22 (0.003-0.01 mg/kg i.v.) increased dialysate DA in the accumbens shell but not in the core or in the medial prefrontal cortex, with bell shaped dose-response curve and an effect at 0.01 mg/kg and a biphasic time-course; systemic AM251 (1.0 mg/kg i.p.) completely prevented the stimulant effect of BB-22 on dialysate DA in the NAc shell. All the other compounds increased dialysate DA in the NAc shell at doses consistent with their *in vitro* affinity   De Luca et al., [@B44]
  5F-PB-22\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  5F-AKB-48\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  STS-135                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

On the other hand, place conditioning tests in animals showed that WIN 55212-2 and HU210 established a robust place aversion (CPA), reversed by the CB1 receptor antagonist/inverse agonist SR 141716A, in a similar way as seen with Δ^9^-THC (Chaperon et al., [@B27]; Cheer et al., [@B28]; Valjent and Maldonado, [@B170]). In addition, the CB1 antagonist/inverse agonist AM281 did not induce conditioned place preference (CPP). However, a pre-treatment of 14 days with AM281 prior to the CPP test with the same drug, showed significant CPP (Botanas et al., [@B19]). Accordingly, it has been hypothesized that the endogenous cannabinoid system in the brain may act as a counter-reward system, and blocking or antagonizing this system would therefore produce the reward (Sañudo-Peña et al., [@B141]; Botanas et al., [@B19]). This could represent a limitation on the therapeutic use of CB1 antagonist/inverse agonists (Seely et al., [@B148]).

The psychopharmacological effects of SC have also been assessed by drug-discrimination studies. These experimental paradigms represent useful tools for evaluating the abuse liability of new drugs that might produce dependence (Solinas et al., [@B156]). Drug-discrimination studies in rats have showed that JWH-018, JWH-250 and CP 47,497-C8-homolog, UR-144, XLR-11, AKB-48 (APINACA), PB-22 (QUPIC), 5F-PB-22, and AB-FUBINACA fully substituted for the discriminative stimulus effects of Δ^9^-THC (Gatch and Forster, [@B67], [@B68]; Wiley et al., [@B184]).

These studies typically serve as an integration of the results obtained by intravenous self-administration (SA) experiments. As for SA studies, while there is some disputable data concerning the reinforcing properties of Δ^9^-THC based on its ability to be persistently self-administered in squirrel monkeys (Tanda et al., [@B160]) but not in rodents, there is still favorable evidence available about SC SA. Thus it has been reported that monkeys, mice and rats acquire and maintain WIN 55.212-2 SA (Martellotta et al., [@B115]; Fattore et al., [@B64]; Justinova et al., [@B92]; Lecca et al., [@B105]). Recently, it has been reported that JWH-018 is self-administered in rodents (**Figure 5**). In the study by De Luca et al. ([@B42]) both rats and mice readily acquired two different operant behaviors: nose-poking into an optical switch (rats) and lever-pressing (mice). Rats self-administered JWH-018 at the dose of 20 μg/kg/infusion in daily 1 h FR3 sessions (**Figure 5A**). As expected, a reduction of SA after the injection of SR141617A (1 mg/kg ip, 30 min prior to the SA session) was observed, consistent with the lack of JWH-018 mediated reinforcement. Intriguingly, nose-poking for JWH-018 significantly increased from the first session (30th session, **Figure 5A**) performed after the administration of SR141617A for 2 consecutive days, confirming that these effects of JWH-018 are mediated through cannabinoid receptors. SA behavior did not decrease when JWH-018 was replaced by vehicle. A control group of rats trained for vehicle, failed to acquire SA behavior. It has been hypothesized that the absence of extinction-like response patterns was unrelated to response-contingent training for JWH-018 because the vehicle failed to induce responding. We think that this probably occurred as a result of a habit learning conditioned by JWH-018, in fact contextual cues were sufficient to maintain responding (De Luca et al., [@B42]). This confirmed previous evidence showing that endocannabinoid signaling through CB1 receptors is significant for the habit formation (Hilário et al., [@B84]). Indeed, in mice, CB1 receptor knockdown can enhance or blunt habit formation, whereas Δ^9^-THC tolerance enhances habit formation; in humans, cannabis use enhances the stimulus-response/habit memory (for review, see Goodman and Packard, [@B74]).

JWH-018 self-administration studies performed in C57BL/6 mice show that animals acquired SA at the dose of 30 μg/kg/infusion in daily 2 h FR1 sessions (**Figure 5B**). Importantly, the specificity of mice responding behavior has been confirmed by the increase of SA under progressive-ratio (PR) schedule of reinforcement. During extinction phase, surprisingly, active lever-pressing did not decrease, while inactive lever-pressing increased becoming superimposable to the active ones. Unlike the SA experiments with rats, in these experiments, the drug associated cues were removed after the first three of a total of 12 sessions during the extinction phase. However, during the JWH-018 reinstatement, SA behavior was immediately reinstated and inactive lever-presses decreased since the SA behavior was specifically regulated by the drug infusion confirming the reinforcing properties of JWH-018. This may also prove that JWH-018 alters cortical processes important for the context updating and the automatic orientation of attention (D\'Souza et al., [@B52]) with consequent disruption of cognitive functioning, emotional processing, and affective states as different SC make in humans (Zimmermann et al., [@B193]). Further research is needed to evaluate the impact of chronic exposure to SC.

Concluding remarks {#s5}
==================

The review of the biomedical data here presented, clearly demonstrates the unsafe nature of these new drugs of abuse. This is particularly alarming since adolescents seem to be the most exposed subjects to these dangerous NPS. Indeed, users are often unaware of the consequences of ingesting synthetic compounds that are sold as "legal alternative" to classical drugs, and their unexpected, sometimes fatal adverse effects. Only awareness can reduce NPS use since stopping their synthesis and diffusion seems to be an improbable task and, morbidity and mortality reports keep increasing as NPS gain popularity worldwide. Awareness campaigns about these substances and their devastating effects should be organized to inform everyone, including clinicians, who should be able to recognize symptoms of intoxication induced by NPS (Simonato et al., [@B153]; Papanti et al., [@B136]; Schifano et al., [@B146]).

Ultimately, this paper intends to be helpful to drive governments and civil society to not underestimate the NPS issue, and to encourage the scientific community to deeply evaluate the pharmacology and toxicological effects of NPS and to develop effective treatments for NPS intoxication. Additionally, this paper intends to be useful for advising law enforcement agencies, which need updated information for the prevention and fight against trafficking and sale of NPS, and in the long run, hopefully contribute to better protect public health and safety.
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![**Chemical structures of Synthetic Cannabinoids**.](fnins-10-00153-g0003){#F3}

![**Effect of JWH-018 administration on DA transmission in the NAc shell, NAc core, and mPFC**. Results are expressed as mean ± SEM of change in DA extracellular levels expressed as the percentage of basal values. The arrow indicates the start of JWH-018 i.p. injection at the dose of 0.25 mg/kg in the NAc shell (*red squares*), NAc core (*blue squares*), and mPFC (*green squares*). Solid symbol: *p* \< 0.05 with respect to basal values; ^\*^*p* \< 0.05 vsNAc core group; § *p* \< 0.05 vs mPFC group; (NAc shell *N* = 10; NAc core *N* = 7; mPFC *N* = 11) (Two-way ANOVA, Tukey\'s HSD post hoc). Adapted from De Luca et al. ([@B42]).](fnins-10-00153-g0004){#F4}

![**JWH-018 self-administration in rats and mice. (A)** JWH-018 self-administration by Sprague-Dawley rats and involvement of CB1 cannabinoid receptors in this behavior. Number of active nose pokes (*circles*) that resulted in JWH-018 infusion (20 μg/kg/infusion) or inactive ones (*triangles*) during each 1-h daily session under FR1 and FR 3 during acquisition (1th to 37th sessions), extinction (38th To 47th sessions) and reacquisition (48th to 54thsessions) phases. On sessions 28th and 29th the effect of SR 141716A on the JWH-018 SA was tested. Results are expressed as mean ± SEM (N sessions 10--47 = 14, sessions 48--54 = 6) ^\*^*p* \< 0.05 vs. inactive nose pokes; ANOVA followed by LSD *post hoc* test. **(B)** JWH-018 self-administration by C57BL/6 mice under fixed (FR1) and progressive (PR) reinforcement schedules. Number of active lever-presses (*circles*) that resulted in JWH-018 infusion (30 μg/kg/inf) or inactive lever-presses (*triangles*) during each 2 h daily session under FR1 (9th--15th sessions), and PR (16th session) reinforcement schedules. Results are expressed as mean ± SEM (*N* = 8), ^\*^*p* \< 0.05 vs. inactive lever- presses; ANOVA followed by LSD *post hoc* test. Adapted from De Luca et al. ([@B42]).](fnins-10-00153-g0005){#F5}
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